NEW YORK, Nov. 1, 2016 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of KemPharm, Inc. (NASDAQ: KMPH) resulting from allegations that KemPharm may have issued materially misleading business information to the investing public.
On April 16, 2015, KemPharm sold 5.09 million shares of stock in its Initial Public Offering, raising $60 million in new capital. On May 5, 2016, KemPharm announced that two committees of the U.S. Food and Drug Administration determined that one of KemPharm's drugs, Apadaz, should be approved for its proposed indication of the management of acute pain that requires an opioid, but voted against inclusion of abuse-deterrent labeling for the product. On this news, shares of KemPharm fell $8.76 per share or over 55% to close at $6.91 per share on May 6, 2016. Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by KemPharm investors. If you purchased shares of KemPharm please visit the firm's website at http://www.rosenlegal.com/cases-975.html for more information. You may also contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at firstname.lastname@example.org or email@example.com. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm. Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Attorney Advertising. Prior results do not guarantee a similar outcome.